Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PURINETHOL vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Acute lymphoblastic leukemia (ALL) maintenance therapy (FDA-approved),Chronic myeloid leukemia (CML) (off-label),Inflammatory bowel disease (Crohn's disease, ulcerative colitis) (off-label),Autoimmune hepatitis (off-label)
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
The terminal elimination half-life of mercaptopurine is approximately 1.5 hours. However, the active metabolite 6-thioguanine nucleotides have a half-life of 5-7 days, correlating with pharmacological effects.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by xanthine oxidase (XO) to 6-thiouric acid (inactive), and via thiopurine methyltransferase (TPMT) to 6-methylmercaptopurine (inactive). Activity of TPMT and NUDT15 affects toxicity. Allopurinol inhibits XO, leading to increased mercaptopurine levels.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 50% of elimination. Biliary excretion contributes to a minor extent (<10%).
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 19% bound to plasma proteins, primarily albumin.
Approximately 85-90% bound to serum albumin.
Volume of distribution is 0.9 L/kg, indicating distribution into total body water.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability is highly variable, ranging from 5% to 37% (mean approximately 16%), due to extensive first-pass metabolism.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
GFR 50-80 m L/min: reduce dose by 25-50%. GFR 10-50 m L/min: reduce dose by 50-75%. GFR <10 m L/min: administer 50% of normal dose every 48 hours or consider alternative.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Induction: 50-75 mg/m² orally once daily. Maintenance: 50-75 mg/m² orally once daily. Adjust based on tolerance and disease response.
Not established; safety and efficacy not determined in pediatric patients.
Start at lower end of dosing range (1.5 mg/kg/day). Monitor renal function and hematologic parameters closely. Reduce dose if significant renal impairment present.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Severe myelosuppression, especially with TPMT or NUDT15 deficiency. The drug is myelotoxic; fatal myelosuppression can occur. Monitor blood counts frequently.
None.
Myelosuppression: monitor CBCs regularly; reduce dose if severe.,TPMT/NUDT15 deficiency: increased risk of severe myelosuppression; consider testing before therapy.,Hepatotoxicity: monitor liver function tests; can cause hepatic veno-occlusive disease.,Immunosuppression: increased risk of infections.,Carcinogenicity: risk of secondary malignancies, especially with prolonged use.,Pregnancy: Category D; may cause fetal harm.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to mercaptopurine,Prior resistance to mercaptopurine (ineffective),Severe myelosuppression (unless benefits outweigh risks),Concomitant use with allopurinol (unless dose-adjusted due to toxicity risk),Pregnancy (absolute contraindication in some contexts)
Hypersensitivity to AURLUMYN or any of its components.
Avoid grapefruit and grapefruit juice as they may increase drug levels. May decrease the effectiveness of warfarin; monitor INR if consuming vitamin K-rich foods. Alcohol consumption should be minimized due to potential hepatotoxicity.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intrauterine growth restriction, preterm delivery, and fetal myelosuppression. Overall, considered teratogenic in humans; avoid use unless benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Present in breast milk in low concentrations. M/P ratio not established. Potential for infant myelosuppression and immunosuppression. Contraindicated in breastfeeding or use with caution; monitor infant for neutropenia and thrombocytopenia.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Increased clearance during pregnancy may require dose adjustment. Monitor therapeutic drug levels (if available) and clinical response. Dose may need to be increased by up to 50% in second and third trimesters; post-partum reduce dose to pre-pregnancy levels.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Purinethol (6-mercaptopurine) is a prodrug converted to active thioguanine nucleotides. Co-administration with allopurinol requires a 65-75% dose reduction of Purinethol due to inhibition of xanthine oxidase. TPMT genotyping or phenotyping is recommended prior to initiation to avoid severe myelosuppression. Monitor CBC and liver enzymes regularly. Avoid live vaccines during therapy.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take this medication exactly as prescribed, usually once daily.,Do not take with allopurinol unless specifically instructed by your doctor, as it may increase side effects.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or jaundice immediately.,Avoid live vaccines (e.g., MMR, varicella) while on this medication.,Drink plenty of fluids to prevent kidney stones from uric acid accumulation.,If you miss a dose, do not double the next dose; take it as soon as remembered if within 12 hours of scheduled time.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PURINETHOL vs AURLUMYN, answered by our medical review team.
PURINETHOL is a Antineoplastic Agent that works by Mercaptopurine is a purine antimetabolite that inhibits purine nucleotide synthesis and metabolism. It is converted intracellularly to 6-thioguanine nucleotides (6-TGNs), which incorporate into DNA and RNA, inhibiting their synthesis and function. It also inhibits de novo purine synthesis via feedback inhibition.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PURINETHOL and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PURINETHOL is: 1.5-2.5 mg/kg orally once daily. Initial dose typically 50-75 mg/m²/day.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PURINETHOL and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PURINETHOL is classified as Category C. First trimester: Increased risk of congenital malformations including craniofacial defects, limb anomalies, and cardiovascular defects. Second and third trimesters: Risk of intraut. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.